Sudden hearing loss due to internal auditory canal metastasis of Her2‑positive gastric cancer: A case report

Kim,Chang‑Hee; Shin,Jung Eun; Roh,Hong Gee; Lee,Jong Sik; Yoon,So Young

doi:10.3892/ol.2014.2058

Sudden hearing loss due to internal auditory canal metastasis of Her2‑positive gastric cancer: A case report

Authors:
- Chang‑Hee Kim
- Jung Eun Shin
- Hong Gee Roh
- Jong Sik Lee
- So Young Yoon
View Affiliations

Affiliations: Department of Otorhinolaryngology‑Head and Neck Surgery, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul 143‑729, Republic of Korea, Department of Radiology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul 143‑729, Republic of Korea, Division of Hematology‑Oncology, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul 143‑729, Republic of Korea
Published online on: April 10, 2014 https://doi.org/10.3892/ol.2014.2058
Pages: 394-396

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Internal auditory canal (IAC) metastasis due to leptomeningeal carcinomatosis (LMC) from gastric cancer (GC) has rarely been reported. Early manifestation of symptoms, such as hearing loss, vertigo and facial paralysis, in cases of IAC metastasis due to LMC may facilitate the early detection of brain metastasis. To the best of our knowledge, the present study is the first to report IAC metastasis due to LMC in human epidermal growth factor receptor 2 (Her2)‑positive GC. This study reports a case of an Her2‑positive GC patient with LMC including IAC metastasis, who presented with acute sensorineural hearing loss, ipsilateral facial paralysis and vertigo during trastuzumab containing chemotherapy. The current study also discusses the early diagnosis and management of this complicated condition, demonstrating that clinical suspicion is key for a prompt diagnosis and proper management of LMC including IAC metastasis in Her2‑positive GC.

View Figures

View References

1	Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Seo HG, et al: Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat. 44:11–24. 2012.
2	Lee JL, Kang YK, Kim TW, Chang HM, Lee GW, Ryu MH, et al: Leptomeningeal carcinomatosis in gastric cancer. J Neurooncol. 66:167–174. 2004.
3	Giglio P, Weinberg JS, Forman AD, Wolff R and Groves MD: Neoplastic meningitis in patients with adenocarcinoma of the gastrointestinal tract. Cancer. 103:2355–2362. 2005.
4	Oh SY, Lee SJ, Lee J, Lee S, Kim SH, Kwon HC, et al: Gastric leptomeningeal carcinomatosis: multi-center retrospective analysis of 54 cases. World J Gastroenterol. 15:5086–5090. 2009.
5	Han JK, Park KH, Lee MS and Lee CK: Gastric carcinoma metastasis to the internal auditory canal. Otol Neurotol. 33:e19–e20. 2012.
6	Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
7	Mir O, Ropert S, Alexandre J, Lemare F and Goldwasser F: High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol. 19:1978–1980. 2008.
8	Cavanna L, Rocchi A, Gorgni S, Ambroggi M, Foroni RP, Ubbiali A, et al: Cerebrospinal fluid cytology diagnosis of HER2-positive leptomeningeal carcinomatosis from HER2-positive metastatic gastric cancer: case report. J Clin Oncol. 29:e367–e368. 2011.
9	Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
10	House JW and Brackmann DE: Facial nerve grading system. Otolaryngol Head Neck Surg. 93:146–147. 1985.
11	Friedman HS, Keir ST and Houghton PJ: The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. Cancer. 97(9 Suppl): 2359–2362. 2003.
12	Streitmann MJ and Sismanis A: Metastatic carcinoma of the temporal bone. Am J Otol. 17:780–783. 1996.
13	Lampson LA: Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier. MAbs. 3:153–160. 2011.
14	Mehta AI, Brufsky AM and Sampson JH: Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. Cancer Treat Rev. 39:261–269
15	Mego M, Sycova-Mila Z, Obertova J, Rajec J, Liskova S, Palacka P, et al: Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis. Breast. 20:478–480. 2011.
16	Platini C, Long J and Walter S: Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol. 7:778–780. 2006.
17	Lin NU, Diéras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, et al: Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 15:1452–1459. 2009.